Docosahexaenoic Acid and Melatonin Prevent Impaired Oligodendrogenesis Induced by Intrauterine Growth Restriction (IUGR)

dc.contributor.authorKühne, Britta Anna
dc.contributor.authorVázquez Aristizabal, Paula
dc.contributor.authorFuentes Amell, Mercè
dc.contributor.authorPla, Laura
dc.contributor.authorLoreiro, Carla
dc.contributor.authorGómez Catalán, Jesús
dc.contributor.authorGratacós Solsona, Eduard
dc.contributor.authorIlla Armengol, Míriam
dc.contributor.authorBarenys Espadaler, Marta
dc.date.accessioned2023-07-31T08:58:16Z
dc.date.available2023-07-31T08:58:16Z
dc.date.issued2022-05-23
dc.date.updated2023-07-31T08:58:16Z
dc.description.abstractIn this study, our aims were to characterize oligodendrogenesis alterations in fetuses with intrauterine growth restriction (IUGR) and to find therapeutic strategies to prevent/treat them using a novel rabbit in vitro neurosphere culture. IUGR was surgically induced in one uterine horn of pregnant rabbits, while the contralateral horn served as a control. Neural progenitor cells (NPCs) were obtained from pup's whole brain and cultured as neurospheres mimicking the basic processes of brain development including migration and cell differentiation. Five substances, chosen based on evidence provided in the literature, were screened in vitro in neurospheres from untreated rabbits: Docosahexaenoic acid (DHA), melatonin (MEL), zinc, 3,3',5-Triiodo-L-thyronine (T3), and lactoferrin (LF) or its metabolite sialic acid (SA). DHA, MEL and LF were further selected for in vivo administration and subsequent evaluation in the Neurosphere Assay. In the IUGR culture, we observed a significantly reduced percentage of oligodendrocytes (OLs) which correlated with clinical findings indicating white matter injury in IUGR infants. We identified DHA and MEL as the most effective therapies. In all cases, our in vitro rabbit neurosphere assay predicted the outcome of the in vivo administration of the therapies and confirmed the reliability of the model, making it a powerful and consistent tool to select new neuroprotective therapies.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec726768
dc.identifier.idimarina9315218
dc.identifier.issn2227-9059
dc.identifier.pmidhttp://hdl.handle.net/2445/201342
dc.identifier.urihttps://hdl.handle.net/2445/201342
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/biomedicines10051205
dc.relation.ispartofBiomedicines, 2022, vol. 10, num. 5, p. 1205
dc.relation.urihttps://doi.org/10.3390/biomedicines10051205
dc.rightscc-by (c) Kühne, Britta Anna et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject.classificationCreixement fetal
dc.subject.classificationMalalties del sistema nerviós
dc.subject.classificationCultiu cel·lular
dc.subject.classificationDiferenciació cel·lular
dc.subject.classificationMelatonina
dc.subject.otherFetal growth
dc.subject.otherNervous system Diseases
dc.subject.otherCell culture
dc.subject.otherCell diferentiation
dc.subject.otherMelatonin
dc.titleDocosahexaenoic Acid and Melatonin Prevent Impaired Oligodendrogenesis Induced by Intrauterine Growth Restriction (IUGR)
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
726768.pdf
Mida:
3.16 MB
Format:
Adobe Portable Document Format